Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association

NEW YORK and LONDON, June 23, 2017 — Akari Therapeutics (NASDAQ: AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European Hematology Association (EHA) in Madrid, Spain containing data for the four patients, to date, who have completed its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria (PNH). Coversin is a second- generation complement inhibitor that is capable of being a self-administered subcutaneous injection.

The poster can be found here: http://akaritx.com/wp-content/uploads/2017/06/EHA_POSTER_23JUN2017.pdf

Click here for full press release